David Gionco insider trades: Stemline Therapeutics (STML) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where David reports to the SEC
Open-market buys and sales
26 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Apr 1, 2020 | STML | ↓ Sell | 11,524 | $4.79 | $55K | Direct | Apr 3, 2020 (2d) |
| Mar 16, 2020 | STML | ↓ Sell | 2,849 | $3.88 | $11K | Direct | Mar 20, 2020 (4d) |
| Mar 10, 2020 | STML | ↓ Sell | 13,857 | $4.98 | $69K | Direct | Mar 13, 2020 (3d) |
| Feb 25, 2020 | STML | ↓ Sell | 9,147 | $6.43 | $59K | Direct | Feb 28, 2020 (3d) |
| Dec 27, 2019 | STML | ↓ Sell | 4,517 | $10.84 | $49K | Direct | Jan 3, 2020 (7d) |
| Mar 12, 2019 | STML | ↓ Sell | 14,022 | $11.11 | $156K | Direct | Mar 15, 2019 (3d) |
| Mar 7, 2019 | STML | ↓ Sell | 1,381 | $11.32 | $16K | Direct | Mar 8, 2019 (1d) |
| Feb 25, 2019 | STML | ↓ Sell | 8,563 | $12.03 | $103K | Direct | Feb 27, 2019 (2d) |
| Mar 12, 2018 | STML | ↓ Sell | 9,183 | $17.38 | $160K | Direct | Mar 14, 2018 (2d) |
| Mar 7, 2018 | STML | ↓ Sell | 1,413 | $16.56 | $23K | Direct | Mar 9, 2018 (2d) |
| Feb 27, 2018 | STML | ↓ Sell | 8,984 | $17.43 | $157K | Direct | Feb 28, 2018 (1d) |
| Jan 17, 2018 | STML | ↓ Sell | 4,250 | $13.43 | $57K | Direct | Jan 19, 2018 (2d) |
| Mar 7, 2017 | STML | ↓ Sell | 1,116 | $8.13 | $9K | Direct | Mar 9, 2017 (2d) |
| Feb 28, 2017 | STML | ↓ Sell | 6,486 | $6.99 | $45K | Direct | Mar 1, 2017 (1d) |
| Jan 19, 2017 | STML | ↓ Sell | 3,593 | $11.46 | $41K | Direct | Jan 24, 2017 (5d) |
| Mar 8, 2016 | STML | ↓ Sell | 1,148 | $5.32 | $6K | Direct | Mar 10, 2016 (2d) |
| Jan 20, 2016 | STML | ↓ Sell | 3,217 | $4.82 | $15K | Direct | Jan 21, 2016 (1d) |
| Jan 20, 2015 | STML | ↓ Sell | 3,311 | $14.22 | $47K | Direct | Jan 21, 2015 (1d) |
| Oct 15, 2013 | SVNT | ↓ Sell | 47,876 | $0.08 | $4K | Direct | Oct 17, 2013 (2d) |
| Mar 6, 2013 | SVNT | ↓ Sell10b5-1 | 1,560 | $0.93 | $1K | Direct | Mar 8, 2013 (2d) |
| Jan 24, 2011 | SVNT | ↓ Sell | 2,032 | $10.00 | $20K | Direct | Jan 27, 2011 (3d) |
| Dec 20, 2010 | SVNT | ↓ Sell | 1,536 | $11.87 | $18K | Direct | Dec 30, 2010 (10d) |
| Feb 16, 2010 | SVNT | ↓ Sell | 1,253 | $13.81 | $17K | Direct | Feb 17, 2010 (1d) |
| Feb 9, 2010 | SVNT | ↓ Sell | 2,037 | $12.77 | $26K | Direct | Feb 11, 2010 (2d) |
| Dec 21, 2009 | SVNT | ↓ Sell | 1,511 | $12.95 | $20K | Direct | Dec 22, 2009 (1d) |
| Sep 15, 2009 | SVNT | ↓ Sell | 18,387 | $15.60 | $287K | Direct | Sep 15, 2009 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About David Gionco's insider trades
David Gionco is Chief Accounting Officer at Stemline Therapeutics (STML). Since Sep 15, 2009, David has reported no open-market purchases and 26 sales worth $1.5M on SEC Form 4. There have been no open-market trades in the last 12 months.
1 sale (0% of the value sold) was made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so it says little about how the insider sees the stock today.
Their filings also include grants and awards (13 filings), shares returned to the company (1 filing), other transactions (1 filing), shares withheld for taxes (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every STML insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.